Drugs.com records the Zepbound KwikPen as the brand's newest presentation
Zepbound now comes in a multi-dose KwikPen alongside its existing single-dose pen and vials, a packaging change tracked in Drugs.com's approval history that could affect how patients get and store their tirzepatide.
Drugs.com updated its Zepbound approval history on February 24, 2026, to add a new presentation: the multi-dose KwikPen. The change means tirzepatide, sold under the brand Zepbound, is now listed in four dosage-form options rather than two [1].
According to the site's records, Zepbound is now supplied as a single-dose pen, a single-dose vial, a multi-dose vial, and the newly added multi-dose KwikPen, described as "single-patient-use" [1]. All six approved strengths are available across these forms. The single-dose pen and vial come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL. The multi-dose vial and KwikPen are packaged differently: each contains enough drug for four doses, ranging from a 10 mg/2.4 mL vial delivering four 2.5 mg doses up to a 60 mg/2.4 mL vial delivering four 15 mg doses [1].
The timeline entry crediting this addition points to a February 23, 2026 approval announcement titled "Zepbound (tirzepatide) Now Available in Multi-Dose KwikPen," listed just above the update in the drug's development history [1]. The sources provided do not include the full text of that announcement, so details such as the exact FDA action date, pricing, or availability timing for the new pen are not yet known from what's here.
Zepbound, made by Eli Lilly, was first approved in November 2023 for chronic weight management in adults with obesity or overweight plus at least one weight-related condition, and later approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity [1]. It works by activating receptors for two natural hormones, GIP and GLP-1, to reduce food intake and slow stomach emptying [1]. In the SURMOUNT-1 trial, people on the highest dose (15 mg) lost about 48 pounds on average, and those on the lowest dose (5 mg) lost about 34 pounds, compared with 7 pounds on placebo [1]. In SURMOUNT-2, people with type 2 diabetes and obesity lost 15.7% of body weight (about 34.4 pounds) on the 15 mg dose and 13.4% (about 29.8 pounds) on the 10 mg dose, versus 3.3% on placebo [1].
Why it matters for patients
A multi-dose pen packs four weekly doses into one device instead of requiring a new single-dose pen or vial for each injection. For patients who currently manage separate single-dose units week to week, this could simplify storage and reduce the number of individual pens or vials handled over a month. The sources do not specify whether the KwikPen changes cost, insurance coverage, or how it is used compared with the existing multi-dose vial, so those practical differences are not yet known.
Zepbound carries a boxed warning for thyroid C-cell tumor risk, and its label lists other warnings including gastrointestinal reactions, acute kidney injury, gallbladder disease, pancreatitis, and hypersensitivity reactions [1]. Common side effects include nausea, diarrhea, vomiting, constipation, and injection site reactions [1]. These risks and warnings apply to the drug itself, not specifically to the new pen format, based on the information provided.
What happens next
Drugs.com's timeline notes the KwikPen approval announcement dated February 23, 2026, one day before the approval history update [1]. Beyond that, the sources do not describe a rollout schedule, availability date, or whether the KwikPen will replace or supplement the existing multi-dose vial. Patients wanting specifics on cost or how to obtain the new pen would need information beyond what is included in the sources reviewed here.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.